Alpha cognition to present q1 2025 zunveyl (benzgalantamine) launch strategy targeting the $2 billion u.s. alzheimer's long-term care market during investor update call

Dallas--(business wire)--alpha cognition inc. (nasdaq: acog) (“alpha cognition”, or the “company”), a biopharmaceutical company committed to developing novel therapies for debilitating neurodegenerative disorders, today announced it will host an investor update call on tuesday, january 28th, 2025 at 4pm est to present its commercial launch strategy for zunveyl (benzgalantamine), an fda-approved treatment for mild-to-moderate alzheimer's disease (ad). the call will focus on the company's plans t.
ACOG Ratings Summary
ACOG Quant Ranking